

# Predictmedix Secures Deployment of Safe Entry Stations at De Beers Forevermark Forum 2022

High Visibility, Revenue Generating Deployment Provides Predictmedix with Strong Industry Validation

**TORONTO, ON / ACCESSWIRE / June 15, 2022** / Predictmedix Inc. (CSE: PMED) (OTCQB: PMEDF) ("Predictmedix" or the "Company"), an emerging provider of rapid health screening solutions powered by a proprietary artificial intelligence (AI), today announced that it has secured a revenue-generating deployment at the DeBeers Forevermark Forum 2022 from June 29 – July 1, 2022.

The Safe Entry Stations will be utilized to screen both guests and staff for signs and symptoms of infectious diseases such as COVID-19. This repeat commercial placement was secured through the Company's South Asia partner, Entertainment Bay, who focuses on serving the live event market and seeks high visibility event placements for the Safe Entry Station.

"We are pleased to announce this repeat commercial placement at De Beer's Forevermark Forum, where hundreds of industry experts gather for a several day event," said Dr. Rahul Kushwah, Interim Chief Executive Officer of Predictmedix. "This placement not only provides incredible visibility and validation for Predictmedix, but it also validates the need for maintaining safety protocols at live events - providing a safe environment for all attendees. Through events such as these, we are seeing strong interest from event organizers and expect to ramp deployments in the quarters ahead with our South Asia distributor, Entertainment Bay.

"It's not only about safeguarding people from COVID-19, but also about identifying those who have symptoms of any infectious diseases, like the cold or flu. Nobody wants to come down with a cold or flu, and we are finding that events have a higher turnout when these safety measures are in place - adding value for all stakeholders," concluded Kushwah.

### About Predictmedix Inc.

Predictmedix (CSE:PMED)(OTCQB:PMEDF) is a leading provider of rapid health screening and remote patient care solutions globally. The Company's Safe Entry Stations - powered by a proprietary artificial intelligence (AI) - use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including infectious diseases such as COVID-19, impairment by drugs or alcohol, or various mental illnesses. Predictmedix's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at www.Predictmedix.com or follow us on Twitter, Instagram or LinkedIn.

### About Entertainment Bay

Entertainment Bay is a leading event production company in India with over 10 years' experience providing a full range of event services and management for companies, organizations and individuals at stadiums, theaters, music venues, hotels and conference event centers. For more information visit <u>www.entertainmentbay.in</u>.

#### **Investor Relations Contact**

Lucas A. Zimmerman MZ Group - MZ North America 949-259-4987 <u>PMEDF@mzgroup.us</u> <u>www.mzgroup.us</u>

## **Caution Regarding Forward-Looking Information:**

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.

Disclaimer: "The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.